Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.
Genetic Variations Linked to Post-Transplant Outcomes in Leukemia Patients
This video examines research that found that certain genetic variations of both leukemia patients undergoing bone marrow transplant and their unrelated donors were associated with poor outcomes.
Stomach Pain in 67-Year-Old Patient
A 67-year-old man presents with gastric pain, and a biopsy is performed. What is your diagnosis?
Short-Course RT With Delayed Surgery Viable in Rectal Cancer
No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.
Next-Generation Sequencing for Lung Cancer in Clinical Practice
This video highlights some of the latest developments guiding precision medicine for lung cancer in clinical practice.
Combined Immunotherapy, Thoracic RT Carries Moderate Toxicity in Lung Cancer
A study of the combination of radiation therapy and immune checkpoint inhibitors for the treatment of advanced lung cancer found a modest risk of side effects.
Quality-of-Life Data Provide Valuable Insights in Lung Cancer Patients
In this interview we discuss how quality-of-life information from patients with lung cancer can be used to help guide treatment and inform outcomes.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
Hodgkin Lymphoma Survivors at High Risk for Second Cancers
Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.
Updated Data Confirm Benefit of Single SBRT Dose for NSCLC
This video examines updated data from a phase II trial that compared a single dose of high-intensity SBRT with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.